Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086624 | 1.00 | KDM4E (0.55) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL1001099 | 1.00 | KDM4E (0.55) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL4664068 | 0.82 | KDM4E (0.70) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL4664072 | 0.82 | KDM4E (0.70) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL4093743 | 0.74 | MAPT (0.64) | KDM4EHSD17B10MAPK1MAPTHPGD | |
| SCHEMBL249817 | 0.71 | ALDH1A1 (0.64) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL14524539 | 0.71 | ALDH1A1 (0.64) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL249816 | 0.71 | ALDH1A1 (0.64) | KDM4EHSD17B10MAPK1CASP1MAPT | |
| SCHEMBL1004133 | 0.70 | ALDH1A1 (0.57) | KDM4EHSD17B10MAPK1MAPTHPGD | |
| SCHEMBL1004132 | 0.70 | ALDH1A1 (0.57) | KDM4EHSD17B10MAPK1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173360-B2 | Cell death inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2270505-A1 | A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF) | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100099106-A1 | CELL DEATH INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-7659267-B2 | 1,3-Benzothiazinone derivatives, process for producing the same use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20060034832-A1 | Cell death inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1500402-A1 | CELL DEATH INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6794383-B2 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030186971-A1 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1325918-A1 | HEART MUSCULAR CELL APOPTOSIS INHIBITORS AND REMEDIES/PREVENTIVES FOR HEART DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186971-A1 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TNNI3, TNNT2, BAX | KDM4E 1355/4885HSD17B10 281/4885MAPK1 480/4885 |
| US-20060034832-A1 | Cell death inhibitor | MIF, TNFSF11, PDCD6IP | KDM4E 3351/4885HSD17B10 3255/4885MAPK1 443/4885 |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | MIF, FOXM1, HMGB3 | KDM4E 3538/4885HSD17B10 309/4885MAPK1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.